



30 June 2023

## Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

### Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

#### Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes withheld (2)
1. To adopt the 2022 Annual Report and Accounts	187,231,295	99.86	260,529	0.14	187,491,824	16.42	4,905,675
2. To approve the Directors' Remuneration Policy	175,511,893	91.34	16,644,001	8.66	192,155,894	16.83	241,605
3. To re-appoint Peter Redmond as Director	161,957,826	86.38	25,531,232	13.62	187,489,058	16.42	4,908,441
4. To re-appoint Alexis Sandler as Director	175,078,447	93.44	12,285,451	6.56	187,363,898	16.41	5,033,601
5. To re-appoint Dr Vladislav Sandler as Director	175,160,284	93.49	12,203,614	6.51	187,363,898	16.41	5,033,601
6. To reappoint the Company's auditor	185,776,647	99.09	1,715,177	0.91	187,491,824	16.42	4,905,675
7. To authorise the Audit Committee to determine the auditor's remuneration	176,309,143	94.04	11,179,915	5.96	187,489,058	16.42%	4,908,441
8. To authorise the Directors to allot equity securities	170,229,487	90.79	17,259,571	9.21	187,489,058	16.42	4,908,441

Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes withheld (2)
9. To disapply pre-emption provisions	156,025,169	89.79	17,751,132	10.21	173,776,301	15.22	18,621,198
10. To reduce the notice period for general meetings	171,582,521	91.51	15,909,303	8.49	187,491,824	16.42	4,905,675

- (1) The Company's issued share capital ("ISC") on 28 June 2023, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,141,999,321 ordinary shares.
- (2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

#### Enquiries:

##### **Hemogenyx Pharmaceuticals plc**

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder  
Peter Redmond, Director

<https://hemogenyx.com>

[headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com)

[peter.redmond@hemogenyx.com](mailto:peter.redmond@hemogenyx.com)

##### **SP Angel Corporate Finance LLP**

Matthew Johnson, Vadim Alexandre, Adam Cowl

Tel: +44 (0)20 3470 0470

##### **Peterhouse Capital Limited**

Lucy Williams, Duncan Vasey, Charles Goodfellow

Tel: +44 (0)20 7469 0930